Comparison
While Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575, Setmelanotide is approved for chronic weight management in patients with POMC, PCSK1, LEPR deficiencies and Bardet–Biedl syndrome by reducing hunger and promoting weight loss92.
While Retatrutide works as a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575, Setmelanotide is a potent synthetic melanocortin-4 receptor (MC4R) agonist derived from a POMC/α-MSH–related sequence that restores downstream MC4R signaling in genetic obesity syndromes3192100.
Retatrutide is 39 amino acids long, whereas Setmelanotide is shorter as it has a length of amino acids. Retatrutide is made up of a sequence of sequence data not available in the current dataset. Setmelanotide is made up of a sequence of sequence data not available in the current dataset.
Retatrutide
Not assigned in the current dataset.
Setmelanotide
POMC